These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23478277)

  • 21. Smoking induces lipoprotein-associated phospholipase A2 in cardiovascular disease free adults: the ATTICA Study.
    Tselepis AD; Panagiotakos DB; Pitsavos C; Tellis CC; Chrysohoou C; Stefanadis C
    Atherosclerosis; 2009 Sep; 206(1):303-8. PubMed ID: 19394616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lp-PLA₂- a novel risk factor for high-risk coronary and carotid artery disease.
    Epps KC; Wilensky RL
    J Intern Med; 2011 Jan; 269(1):94-106. PubMed ID: 21054587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature.
    Gregson J; Stirnadel-Farrant HA; Doobaree IU; Koro C
    Atherosclerosis; 2012 Nov; 225(1):11-21. PubMed ID: 22784637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipoprotein-associated phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease.
    Massot A; Pelegri D; Penalba A; Arenillas J; Boada C; Giralt D; Ribó M; Molina CA; Rosell A; Alvarez-Sabín J; Chacón P; Rovira A; Delgado P; Montaner J
    Atherosclerosis; 2011 Sep; 218(1):181-7. PubMed ID: 21620406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study.
    Nambi V; Hoogeveen RC; Chambless L; Hu Y; Bang H; Coresh J; Ni H; Boerwinkle E; Mosley T; Sharrett R; Folsom AR; Ballantyne CM
    Stroke; 2009 Feb; 40(2):376-81. PubMed ID: 19095974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study.
    Suzuki T; Solomon C; Jenny NS; Tracy R; Nelson JJ; Psaty BM; Furberg C; Cushman M
    Circ Heart Fail; 2009 Sep; 2(5):429-36. PubMed ID: 19808373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study.
    Nelson TL; Biggs ML; Kizer JR; Cushman M; Hokanson JE; Furberg CD; Mukamal KJ
    J Clin Endocrinol Metab; 2012 May; 97(5):1695-701. PubMed ID: 22399516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.
    Ryu SK; Mallat Z; Benessiano J; Tedgui A; Olsson AG; Bao W; Schwartz GG; Tsimikas S;
    Circulation; 2012 Feb; 125(6):757-66. PubMed ID: 22230483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis.
    Stewart RA; White HD
    Curr Atheroscler Rep; 2011 Apr; 13(2):132-7. PubMed ID: 21207201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral artery disease, biomarkers, and darapladib.
    Berger JS; Ballantyne CM; Davidson MH; Johnson JL; Tarka EA; Lawrence D; Trivedi T; Zalewski A; Mohler ER
    Am Heart J; 2011 May; 161(5):972-8. PubMed ID: 21570531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events.
    Nambi V; Ballantyne CM
    Curr Atheroscler Rep; 2006 Sep; 8(5):374-81. PubMed ID: 16901407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma.
    Tellis CC; Tselepis AD
    Biochim Biophys Acta; 2009 May; 1791(5):327-38. PubMed ID: 19272461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of lipoprotein-associated phospholipase A2 in atherosclerosis.
    Lavi S; Herrmann J; Lavi R; McConnell JP; Lerman LO; Lerman A
    Curr Atheroscler Rep; 2008 Jun; 10(3):230-5. PubMed ID: 18489851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipoprotein-associated phospholipase A(2): a promising vascular-specific marker for screening cardiovascular risk?
    Lee JH; Engler MM
    Prog Cardiovasc Nurs; 2009 Dec; 24(4):181-9. PubMed ID: 20002343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
    Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
    Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Role of secreted and lipoprotein-associated phospholipase A2 in cardiovascular risk].
    Ferri N; Corsini A
    G Ital Cardiol (Rome); 2014 Dec; 15(12):664-9. PubMed ID: 25533115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: possible contribution to an atherogenic lipoprotein profile.
    Dullaart RP; Constantinides A; Perton FG; van Leeuwen JJ; van Pelt JL; de Vries R; van Tol A
    J Clin Endocrinol Metab; 2011 Apr; 96(4):1077-84. PubMed ID: 21252249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
    Charniot JC; Khani-Bittar R; Albertini JP; Giral P; Cherfils C; Cosson C; Guillerm E; Leprince P; Gandjbakhch I; Bonnefont-Rousselot D
    Int J Cardiol; 2013 Sep; 168(1):132-8. PubMed ID: 23103135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.
    Ridker PM; MacFadyen JG; Wolfert RL; Koenig W
    Clin Chem; 2012 May; 58(5):877-86. PubMed ID: 22419750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.